Status:

TERMINATED

The Individualized M(X) Drug-resistant TB Treatment Strategy Study

Lead Sponsor:

Centre for the AIDS Programme of Research in South Africa

Conditions:

Tuberculosis, Multidrug-Resistant

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

This is a randomized controlled clinical trial comparing treatment success of a gene-derived individualized drug-resistant Tuberculosis regimen to a standard Tuberculosis regimen based on South Africa...

Detailed Description

When drug resistance is detected by molecular methods such as the Xpert MTB/RIF assay, second-line Multi Drug-Resistant (MDR) Tuberculosis treatment is started in the complete absence of detailed resi...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Adults ≥ 18 years of age
  • Pulmonary Tuberculosis
  • Microbiological confirmation \[e.g. GeneXpert Mycobacterium Tuberculosis (MTB) detected and Rifampicin (RIF) resistant and / Line Probe Assay (LPA)\] of Multi drug-resistant tuberculosis (MDR-TB) / Pre-Extremely drug-resistant tuberculosis (Pre-XDR-TB) / Extremely drug-resistant tuberculosis (XDR-TB)
  • Capacity for providing informed consent
  • HIV status - HIV infected and uninfected patients are allowed in the study:
  • Patients already on antiretroviral treatment (ART) will be allowed in the study. The antiretroviral treatment regimen will be evaluated for any contraindications to the drugs used.
  • HIV infected patients at any CD4 count irrespective of antiretroviral treatment commencement and duration will be included in the study
  • Exclusion Criteria:
  • Persons suffering from any serious acute condition.
  • Any other chronic or clinically significant medical condition that in the opinion of the attending clinician would render the patient unsuitable for participation in the study.

Exclusion

    Key Trial Info

    Start Date :

    June 14 2017

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 19 2022

    Estimated Enrollment :

    205 Patients enrolled

    Trial Details

    Trial ID

    NCT03237182

    Start Date

    June 14 2017

    End Date

    December 19 2022

    Last Update

    September 1 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    King Dinuzulu Hospital

    Durban, KwaZulu-Natal, South Africa